Cambridge Investment Research Advisors, Inc. Cardiol Therapeutics Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 61,001 shares of CRDL stock, worth $96,991. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,001
Previous 116,131
47.47%
Holding current value
$96,991
Previous $235,000
48.51%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CRDL
# of Institutions
45Shares Held
5.07MCall Options Held
5.2KPut Options Held
9.5K-
Tejara Capital LTD London, X01.77MShares$2.82 Million1.67% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.17MShares$1.86 Million0.46% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$1.27 Million0.36% of portfolio
-
Lion Street Advisors, LLC273KShares$434,5160.19% of portfolio
-
Foundations Investment Advisors, LLC162KShares$257,5000.01% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $98.5M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...